afatinib + anti-EGF vaccine

Afatinib + anti-EGF vaccine is a combination therapy consisting of afatinib, an oral irreversible tyrosine kinase inhibitor (TKI) targeting the ErbB family of receptors (including EGFR), and an anti-epidermal growth factor (EGF) vaccine designed to induce antibodies against EGF. This approach aims to both inhibit EGFR signaling directly via TKI activity and reduce ligand-driven activation by neutralizing circulating EGF through vaccination-induced antibodies. The combination has been studied in advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations, showing promising efficacy, sustained immunogenic response, and manageable safety profile in early-phase clinical trials[1][2][3][5]. The rationale is that dual blockade—by inhibiting the receptor with afatinib and depleting its ligand with the vaccine—may enhance antitumor effects and delay resistance compared to TKI monotherapy.

Brand names

GiotrifCIMAvax-EGF

Other names

afatinib + EGF-PTIafatinib + epidermal growth factor pathway targeting immunisation